Literature DB >> 17093150

Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons.

Amira N Kassis1, Peter J H Jones.   

Abstract

BACKGROUND: More than 50 studies have reported substantial reductions in plasma lipid concentrations in response to 2-40 mg Cuban sugar cane policosanol (SCP) mixtures/d. However, several animal and human trials conducted outside of Cuba that used non-Cuban mixtures have failed to reproduce the efficacy of policosanols observed in earlier studies.
OBJECTIVE: The objective was to evaluate lipid-modulating actions of the authentic Cuban SCPs on plasma lipids in healthy hypercholesterolemic volunteers.
DESIGN: Twenty-one volunteers consumed, under supervision, 10 mg SCPs/d or a placebo incorporated in margarine as an afternoon snack, for a period of 28 d with the use of a randomized, double-blind crossover study design. Subjects maintained their habitual diet and physical activity and were weighed daily throughout the study period. Blood was collected at days 1, 2, 28, and 29 of the feeding trial, and lipid concentrations were measured.
RESULTS: Body weights did not vary significantly throughout the trial and did not affect plasma lipid values. No significant difference was observed between treatment and control groups in plasma total, LDL-, HDL-cholesterol, and triacylglycerol concentrations.
CONCLUSION: Present results show no beneficial effects of Cuban SCPs on lipid indicators in hypercholesterolemic persons and question the clinical usefulness of policosanol mixtures as cholesterol-lowering neutraceutical agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093150     DOI: 10.1093/ajcn/84.5.1003

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  7 in total

1.  Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial.

Authors:  Barbara Swanson; Joyce K Keithley; Beverly E Sha; Louis Fogg; Judith Nerad; Richard M Novak; Oluwatoyin Adeyemi; Gregory T Spear
Journal:  Altern Ther Health Med       Date:  2011 Mar-Apr       Impact factor: 1.305

2.  Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy.

Authors:  James M Backes; Cheryl A Gibson; Janelle F Ruisinger; Patrick M Moriarty
Journal:  Lipids       Date:  2011-07-08       Impact factor: 1.880

3.  Letters.

Authors:  Alan Gaby
Journal:  Integr Med (Encinitas)       Date:  2021-10

4.  Regulation of HMGCoA reductase activity by policosanol and octacosadienol, a new synthetic analogue of octacosanol.

Authors:  Simonetta Oliaro-Bosso; Emanuela Calcio Gaudino; Stefano Mantegna; Enrico Giraudo; Claudia Meda; Franca Viola; Giancarlo Cravotto
Journal:  Lipids       Date:  2009-09-11       Impact factor: 1.880

5.  Sugar cane policosanols do not reduce LDL oxidation in hypercholesterolemic individuals.

Authors:  Amira N Kassis; Stan Kubow; Peter J H Jones
Journal:  Lipids       Date:  2009-04-01       Impact factor: 1.880

6.  Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects.

Authors:  Jae-Yong Kim; Seong-Min Kim; Suk-Jeong Kim; Eun-Young Lee; Jae-Ryong Kim; Kyung-Hyun Cho
Journal:  Int J Mol Med       Date:  2017-02-24       Impact factor: 4.101

7.  Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial.

Authors:  Amira N Kassis; Peter J H Jones
Journal:  Lipids Health Dis       Date:  2008-04-30       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.